ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders

Globe and Mail

5 days ago

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of iTeos Therapeutics, Inc. (NASDAQ: ITOS) to Concentra Biosciences, LLC is fair to iTeos shareholders. Under the terms of the proposed transaction, Concentra will acquire iTeos for $10.047 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of iTeos in excess of $475 million; and (ii) 80% of any net proceeds received from any disposition of certain of iTeos' product candidates that occurs within six months following the closing.
Halper Sadeh encourages iTeos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at [phone] or [e-mail] or [e-mail].
The investigation concerns whether iTeos and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for iTeos shareholders; (2) determine whether Concentra is underpaying for iTeos; and (3) disclose all material information necessary for iTeos shareholders to adequately assess and value the merger consideration.
On behalf of iTeos shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.